Major pharmaceutical consolidation as GSK pursues targeted cancer therapies through strategic acquisition.

Gene-editing therapy now cleared for youngest pediatric patients with sickle cell disease and beta-thalassemia.

mRNA platform company gains analyst confidence with focus on oncology and AI-powered drug development.

Intellia Therapeutics approaches pivotal trial data as CRISPR-based in vivo gene editing advances.

Triple therapy remains cornerstone of CF management as company strengthens position in lung disease.

Gene therapy developer advances Huntington's disease candidate with regulatory pathway clarification and analyst upgrades.

mRNA platform applications expand beyond infectious disease into oncology and personalized medicine.

Lung-focused biotech secures funding to test investigational treatment in late-stage development.

Novel approach to cellular senescence enters clinic after preclinical validation of aging reversal mechanisms.

Graft-versus-host disease treatment shows dramatic efficacy improvement in allogeneic stem cell transplant patients.

Pharma company adds first-in-class BK polyomavirus antibody through strategic acquisition.

Investigational therapy targeting hereditary angioedema enters expedited regulatory pathway.

First-ever genetic treatment for deafness now available at no cost to qualifying patients.

Biotech developer of targeted nuclear medicine compounds builds on clinical progress.

South Korean manufacturer advances PD-1 inhibitor biosimilar as competition in immuno-oncology grows.

German biotech pursues next-generation CAR-T therapy designed for difficult-to-treat solid cancers.

Danish biotech expands oncology portfolio through partnership centered on cancer immunotherapy.

Biotech company's rapid share price gain raises debate over fair valuation amid pipeline development.